Actuate Therapeutics, Inc.
Austin Koukol has had a diverse range of work experience in the field of clinical research. Starting in 2019, they worked as a Research Consultant at Monopar Therapeutics, Inc. for three months. In 2020, they joined Monopar Therapeutics Inc. and held roles as a Clinical Trial Assistant I, Clinical Trial Assistant II, and Clinical Research Associate I over a span of two years. In 2022, they joined PPD as a Clinical Research Associate II for eight months before moving on to their current position as a Project Manager of Operations and Translational Science at Actuate Therapeutics, Inc.
Austin Koukol earned a Bachelor of Science (BS) degree in Integrative Biology from the University of Illinois Urbana-Champaign. In addition, Austin obtained certification in the "GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus) Course" from the CITI Program in December 2020.
This person is not in any teams
This person is not in any offices
Actuate Therapeutics, Inc.
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, andcommercialize new agents that target GSK-3β.Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.